NASDAQ:ORPH Orphazyme A/S (ORPH) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free ORPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.57▼$2.2152-Week Range N/AVolume941,400 shsAverage Volume1.37 million shsMarket Capitalization$30.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Orphazyme A/S alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Orphazyme A/S Stock (NASDAQ:ORPH)Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. ORPH Stock News HeadlinesApril 20, 2024 | msn.comPhase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patientsApril 19, 2024 | msn.comOlympic torch makes Acropolis overnight stop a week before handover to Paris organizersApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 18, 2024 | nbcnews.comInside Gen Alpha’s controversial obsession with skincareApril 13, 2024 | msn.comIt’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start?April 12, 2024 | msn.comLysine Is Important for the Body, and Is Generally a Safe SupplementApril 11, 2024 | markets.businessinsider.comZevra Therapeutics: Strong Buy on Strategic Financing and Promising Drug PortfolioApril 8, 2024 | msn.comFrom fungi to feast: The rise of Mycoprotein as a sustainable protein solutionApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 3, 2024 | msn.comAsk A Doctor: What Diseases Cause Encephalopathy?April 1, 2024 | msn.comChemists discover a key protein in how lysosomes workMarch 28, 2024 | msn.comOrry refuses to shake woman’s hand citing ‘germs,’ threatens legal action after her videoMarch 28, 2024 | msn.comA Guide To Pokémon's Poison TypeMarch 18, 2024 | msn.comUnderstanding what causes trastuzumab's cardiotoxicityMarch 16, 2024 | msn.comHow a brash, red-haired orphan from P.E.I. continues to be a worldwide sensationMarch 14, 2024 | msn.comSindica - A Novel, Patented Post-emergence Herbicide for Sugarcane from AtulMarch 12, 2024 | msn.comSharing a Drink With Orphaned Opossum BabiesMarch 12, 2024 | msn.comZevra adds bull at William Blair despite delay in arimoclomol decisionMarch 11, 2024 | msn.com'Why haven't they shown us the original photo?' Anti-monarchist FUMES over Kate's apology - ‘Doesn't explain anything’March 10, 2024 | nytimes.comA.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the MarketMarch 5, 2024 | msn.comAlnylam’s experimental drug for high blood pressure yields encouraging resultsMarch 4, 2024 | marketwatch.comFDA Extends Review of Zevra's Arimoclomol by Three MonthsFebruary 23, 2024 | msn.comLadybug scents offer a more ecologically friendly way to protect cropsFebruary 23, 2024 | msn.comGen Alpha have a say on which names they consider to be 'old'February 23, 2024 | yahoo.comOne Piece: Is S-Hawk the Strongest Seraphim in the Series?February 22, 2024 | msn.comWhat Is The History Of Phenylketonuria? A Review By DoctorsJanuary 31, 2024 | msn.comNew Horizons in Chemical Biology: A Novel Approach to Synthesize Dibenzothiophene S-OxidesSee More Headlines Receive ORPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orphazyme A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ORPH CUSIPN/A CIK1764791 Webwww.orphazyme.com Phone45-2898-9055FaxN/AEmployees141Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.14 Current Ratio1.80 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / BookN/AMiscellaneous Outstanding Shares35,312,000Free FloatN/AMarket Cap$30.72 million OptionableNot Optionable Beta1.68 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Anders Fink Vadsholt M.B.A. (Age 52)M.Sc., MBA, Chief Financial Officer Comp: $924.24kMr. Christophe Bourdon M.B.A. (Age 51)Chief Exec. Officer Dr. Thomas Kirkegaard Jensen Ph.D. (Age 44)Co-Founder & Chief Scientific Officer Ms. Molly Carey PoarchHead of Global CommunicationsDr. Thomas Blaettler (Age 54)Chief Medical Officer Ms. Molly Painter (Age 45)Pres of Orphazyme US, Inc. More ExecutivesKey CompetitorsNRx PharmaceuticalsNASDAQ:NRXPDaré BioscienceNASDAQ:DAREImmunoPrecise AntibodiesNASDAQ:IPAAcurx PharmaceuticalsNASDAQ:ACXPAprea TherapeuticsNASDAQ:APREView All Competitors ORPH Stock Analysis - Frequently Asked Questions When did Orphazyme A/S IPO? Orphazyme A/S (ORPH) raised $100 million in an initial public offering (IPO) on Tuesday, September 29th 2020. The company issued 7,600,000 shares at $13.13 per share. BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Danske Markets was co-manager. This page (NASDAQ:ORPH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orphazyme A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
